The BMP2 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Ca Ski cervical cancer line, targeting the BMP2 gene. This loss-of-function model eliminates BMP2 ligand secretion, enabling detailed study of BMP2-dependent signaling in an HPV-positive carcinoma background. The polyclonal product provides a heterogeneous population with diverse gene-disruption events, avoiding single-cell clonal biases and allowing robust investigation of autocrine and paracrine signaling roles.
The Ca Ski host cell line, derived from an epidermoid cervical carcinoma metastasis, is positive for HPV16 and widely used to study HPV-associated malignancy. These cells express viral oncogenes E6 and E7, which inactivate p53 and Rb, driving proliferation and immortalization. Their epithelial phenotype and metastatic capacity provide a clinically relevant context for investigating tumor progression.
BMP2 encodes a secreted ligand of the TGF-?? superfamily with essential functions in osteoblast differentiation, bone formation, and developmental processes. It signals through receptor complexes comprising BMPR1A or BMPR1B and BMPR2, leading to phosphorylation of SMAD1/5/8. These activated SMADs partner with SMAD4 to regulate transcription of target genes including Id1, Id2, Runx2, Sp7, ALPL, and BGLAP. Extracellular antagonists such as Noggin, Chordin, and Gremlin, along with heparan sulfate proteoglycans, modulate pathway activity. Upstream regulators including TNF-??, IL-1??, TGF-??1, estrogen, mechanical stress, and Runx2 influence BMP2 expression. Knockout of BMP2 therefore abolishes ligand production, disrupting downstream SMAD1/5/8 phosphorylation and transcriptional responses.
In cervical cancer, BMP2 signaling has been implicated in modulating cell migration, invasion, and epithelial-to-mesenchymal transition (EMT). The interaction between BMP2 pathways and HPV16 oncoproteins, such as E6 and E7, may contribute to the aggressive metastatic phenotype. This knockout model enables researchers to dissect BMP2-dependent mechanisms in Ca Ski cells, delineating specific contributions to these processes. Additionally, given BMP2’s potent osteogenic activity, this model is uniquely suited for exploring bone metastasis, which frequently occurs in advanced cervical carcinoma patients.
The BMP2 Knockout Ca Ski Polyclonal Cells are ideal for a wide range of research applications, including functional studies of BMP2 in cervical cancer invasion and metastasis, investigation of BMP signaling crosstalk with HPV oncogenes, bone metastasis research, EMT and cancer stem cell studies, and pharmacological screening of BMP2 pathway inhibitors. Compatible experimental techniques include Western blotting for BMP2 and phospho-SMAD1/5/8, RT-qPCR for Id1 and Runx2, ELISA for secreted BMP2, Transwell migration and invasion assays, osteogenic differentiation assays, RNA-seq transcriptomic profiling, cell proliferation assays, and flow cytometry for apoptosis and stem cell markers. For further information or technical support, please contact Ascent Research.
